Preserving hope for patients with Heart Failure with Preserved Ejection Fraction (HFpEF)?

Although guideline-directed medical therapy substantially improves morbidity and mortality in patients with heart failure with reduced ejection fraction (HFrEF), treatments that clearly improve outcomes in those with HF and an EF >40% remain elusive. Unfortunately, the incidence and prevalence of HF are expected to substantially increase in the coming decades.  More evidence and effective treatments for those with HF with preserved ejection fraction are clearly needed.  Enter the EMPEROR-Preserved trial.

Guest Authors:  Gabrielle Givens, PharmD, BCPS and Robert Parker, PharmD

Music by Good Talk